
Rezo: A biopharma company revolutionizing drug development with a disease-agnostic network biology platform.
Founded with the mission to revolutionize drug development, Rezo Therapeutics is a biopharma company leveraging a disease-agnostic, fully-integrated network biology platform. Their core vision is to redefine the understanding of human diseases and enhance the ability to treat them effectively. By mapping disease networks, Rezo aims to unlock new insights and opportunities in drug discovery, targeting a broad spectrum of conditions without being confined to specific diseases.
Rezo Therapeutics has attracted notable investors and industry experts who believe in their innovative approach to drug development. The company has made significant strides in advancing its platform, contributing to a deeper understanding of disease mechanisms and potential therapeutic targets. Their impact on the biopharma industry is marked by their commitment to increasing the success rate of drug development, ultimately aiming to improve patient outcomes across various diseases.

Algen Biotechnologies
algenbio.com

ReviR Therapeutics
revirtx.com

Rejuveron Life Sciences
rejuveron.com

Reactive Biosciences
reactivebio.com

Empirico
empiricotx.com

Reservoir Neuroscience
reservoirneuro.com

Exo Therapeutics

Ensem Therapeutics
ensemtx.com

Ventus Therapeutics

Reset Pharmaceuticals

Unravel Biosciences
unravel.bio

Actio Biosciences
actiobio.com

NeuroX1
neurox1.com

BioXcel Therapeutics

TRex Bio
trex.bio
Companies similar to Rezo Therapeutics include Algen Biotechnologies, ReviR Therapeutics, Rejuveron Life Sciences and Reactive Biosciences.
Rezo Therapeutics' headquarters is located in South San Francisco, CA, US.
Rezo Therapeutics' most recent funding round was for $78M (USD) in November 2022.
As of Nov 17, 2022, Rezo Therapeutics has raised a total of $78M (USD).
Rezo Therapeutics has 30 employees as of Feb 5, 2024.